home / stock / ktra / ktra quote
Last: | $0.286 |
---|---|
Change Percent: | -0.14% |
Open: | $0.2849 |
Close: | $0.286 |
High: | $0.289 |
Low: | $0.281 |
Volume: | 2,032,650 |
Last Trade Date Time: | 07/16/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.286 | $0.2849 | $0.286 | $0.289 | $0.281 | 2,032,650 | 07-16-2024 |
$0.2845 | $0.28 | $0.2845 | $0.2998 | $0.28 | 2,738,166 | 07-15-2024 |
$0.2899 | $0.274 | $0.2899 | $0.299 | $0.27 | 3,841,242 | 07-12-2024 |
$0.2734 | $0.27 | $0.2734 | $0.2928 | $0.2699 | 3,063,653 | 07-11-2024 |
$0.2715 | $0.273 | $0.2715 | $0.28 | $0.2611 | 3,150,731 | 07-10-2024 |
$0.2759 | $0.2928 | $0.2759 | $0.2958 | $0.273 | 3,629,912 | 07-09-2024 |
$0.2795 | $0.33 | $0.2795 | $0.3375 | $0.2731 | 8,304,120 | 07-08-2024 |
$0.3 | $0.2654 | $0.3 | $0.3285 | $0.2654 | 13,754,334 | 07-05-2024 |
$0.2765 | $0.2655 | $0.2765 | $0.2942 | $0.2521 | 4,023,932 | 07-04-2024 |
$0.2765 | $0.2655 | $0.2765 | $0.2942 | $0.2521 | 4,023,932 | 07-03-2024 |
$0.2591 | $0.2852 | $0.2591 | $0.295 | $0.255 | 5,955,916 | 07-02-2024 |
$0.2975 | $0.29 | $0.2975 | $0.3142 | $0.2802 | 8,328,594 | 07-01-2024 |
$0.2701 | $0.2551 | $0.2701 | $0.2713 | $0.2202 | 9,686,164 | 06-28-2024 |
$0.2802 | $0.343 | $0.2802 | $0.375 | $0.275 | 25,265,795 | 06-27-2024 |
$0.3269 | $0.3 | $0.3269 | $0.3576 | $0.3 | 19,028,200 | 06-26-2024 |
$0.2984 | $0.252 | $0.2984 | $0.308 | $0.25 | 12,195,120 | 06-25-2024 |
$0.2623 | $0.2551 | $0.2623 | $0.268 | $0.241 | 8,545,172 | 06-24-2024 |
$0.2471 | $0.3085 | $0.2471 | $0.3368 | $0.24 | 38,292,269 | 06-21-2024 |
$0.2749 | $0.2051 | $0.2749 | $0.2997 | $0.19 | 47,248,824 | 06-20-2024 |
$0.216 | $0.1974 | $0.216 | $0.227 | $0.195 | 25,202,443 | 06-19-2024 |
News, Short Squeeze, Breakout and More Instantly...
Kintara Therapeutics Inc Com Company Name:
KTRA Stock Symbol:
NASDAQ Market:
Kintara Therapeutics Inc Com Website:
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor PR Newswire KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remod...
Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones PR Newswire SAN DIEGO , July 1, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara"), a biopharmaceutic...